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During the past few decades, intensive collaborative research in the fields of
chronic and acute inflammatory disorders has resulted in a better understanding
of the pathophysiology and diagnosis of these diseases. Modern therapeutic ap-
proaches are still not satisfactory and shock, sepsis and multiple organ failure
remain the great challenge in intensive care medicine. However, the treatment of
inflammatory diseases like rheumatoid arthritis, ulcerative colitis or psoriasis also
represents an unresolved problem.
Many factors contribute to the complex course of inflammatory reactions.
Microbiological, immunological and toxic agents can initiate the inflammatory
response by activating a variety of humoral and cellular mediators. In the early
phase of inflammation, excessive amounts of interleukins and lipid-mediators are
released and play a crucial role in the pathogenesis of organ dysfunction. Ara-
chidonic acid (AA), the mother substance of the pro-inflammatory eicosanoids,
is released from membrane phospholipids in the course of inflammatory activa-
tion and is metabolised to prostaglandins and leukotrienes.
Various strategies have been evaluated to control the excessive production of
lipid mediators on different levels of biochemical pathways, such as inhibition
of phospholipase A2, the trigger enzyme for release of AA, blockade of cyclo-
oxygenase and lipoxygenase pathways and the development of receptor antago-
nists against platelet activating factor and leukotrienes. Some of these agents exert
protective effects in different inflammatory disorders such as septic organ failure,
rheumatoid arthritis or asthma, whereas others fail to do so. Encouraging results
have been obtained by dietary supplementation with long chain -3 fatty acids
like eicosapentaenoic acid (EPA). In states of inflammation, EPA is released to
compete with AA for enzymatic metabolism inducing the production of less in-
flammatory and chemotactic derivatives.
                                                                             
                                                  
Inflammatory processes are the physiological
response of the organism to different stimuli such
as trauma, infections or immunological mecha-
nisms. The inflammatory reaction is characterised
by the stimulation of humoural and cellular medi-
ator systems and the release of a great variety of
inflammatory mediators which result in alterations
in microvascular tone and permeability. The prod-
ucts of the classical cascade systems and various
other mediators are capable of activating the lipid
mediator syntheses which are essentially involved
in the regulation of the complex inflammatory re-
action.[1]
Prostaglandins such as prostaglandin (PG) E2
and PGI2 (prostacyclin) induce oedema formation
(tumour) and vasodilation (rubor), and contribute
to the development of hyperalgesia at the site of
inflammation (dolor). Fatty acid peroxides and
leukotrienes additionally increase local permeabil-
ity and are potent chemoattractants for neutrophil
granulocytes, resulting in a further accumulation of
phagocytes in the microcirculation. The inflamma-
tory activity is further maintained by platelet acti-
vating factor (PAF), which is another important
lipid mediator stimulating neutrophils and partially
influencing the vascular tone and permeability.
Moreover, PAF is a chemotactic agent, which con-
tributes to leucocyte-mediated injury in inflamma-
tory processes. The aim of this article is to give a
brief update of the pathophysiological impact of
lipid mediators in inflammatory disorders and to
summarise the recent development of therapeutic
approaches.
The precursors of eicosanoids are lipid com-
pounds of cellular membranes. The activation of
the phospholipase A2 (PLA2) family induces the
mobilisation of fatty acids, particularly arachi-
donic acid (AA), from the membrane lipid pool for
the synthesis of lipid mediators at the site of cellu-
lar damage or inflammation. In individuals without
relevant dietary intake of -3 polyunsaturated fatty
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acids ( -3-PUFAs, contained in fish oils), AA is
predominantly released from the phospholipid
pool of cellular membranes, which is metabolised
by 2 major pathways to pro-inflammatory media-
tors[2] (fig. 1). The vaso- and bronchoconstrictive
metabolites thromboxane A2 (TXA2) and PGF2
are produced via the cyclooxygenase (COX) path-
way. The TXA2-induced vaso- and bronchospasm
predominates over the relaxing effects of simulta-
neously generated PGI2 and PGE2 on smooth mus-
cle cells of vessels and bronchioli. The pattern of
eicosanoids formed depends on the enzyme con-
tent of the particular cells[3] (fig. 2).
Alternatively, AA is metabolised by 5-lipoxy-
genase, thereby forming chemotactic leukotriene
(LT) B4 and the slow reacting substance of anaphy-
laxis (SRS-A) identified in 1980 as LTC4, LTD4
and LTE4[4], which increase capillary permeabil-
ity. In the case of increased membrane lipid content
of -3 fatty acids, eicosapentaenoic acid (EPA)
competes with AA for metabolism via the COX and
lipoxygenase pathways.[5] The EPA-derived meta-
bolites have lower biological activity[6] than the
analogous AA derivatives. In comparison with the
AA-derived TXA2, the EPA-derived COX-product
of the 3-series TXA3 has considerably reduced pro-
aggregatory and vasoconstrictive properties, while
PGI3 possesses similar antiaggregatory and vas-
odilative effects to those of PGI2.
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Enzymatic conversion of EPA generates the 5-
series leukotrienes (LTB5, C5, D5, E5) which have
partially antagonistic biological effects compared
with AA derivatives.[7] The vasoconstrictive and
chemotactic potency of LTB5 is 2 orders of magni-
tude lower than the activity of LTB4.[8] In addition,
the generation of proinflammatory PAF is reduced
by EPA via interference with the PAF precursor
pool.[9] Figure 1 provides an overview of the ex-
perimentally and clinically relevant possibilities of
eicosanoid pathway modulation.
Activation of the PLA2 family is a key step in
the production of precursors for the biosynthesis of
inflammatory lipid mediators. Inhibition of this en-
zyme could result in the suppression of 3 important
classes of inflammatory lipids (PGs, LTs and PAF),
which offers an attractive therapeutic approach to
the design of novel agents for the treatment of in-
flammation and tissue injury. The PLA2 family is
a series of enzymes involved in phospholipid ca-
tabolism. More than 150 PLA2 amino acid se-
quences are currently available in protein sequence
databases.
PLA2 exists in both extracellular and intracel-
lular forms. Secretory PLA2 (sPLA2) are Ca++-
dependent enzymes (molecular weight 14 kD, reg-
ulated by millimolar amounts of Ca++) which are
classified in 2 groups on the basis of their primary
structures.[10] Secretory nonpancreatic PLA2 has
been implicated in the pathogenesis of articular in-
flammation in rheumatoid arthritis, whereas pan-
creatic PLA2 contributes to the tissue damage as-
sociated with acute pancreatitis. The cytosolic
PLA2 (cPLA2) is an 85.2 kD enzyme with substrate
specificity for AA. It is found in most cells and
tissues and is regulated by Ca++ in the micromolar
range.[11] cPLA2 plays an important role in both the
rapid and the prolonged cellular responses occur-
ring during inflammatory processes.
Accordingly, in the past few years it has been
proposed that PLA2 inhibitors be applied to the
control of inflammatory diseases. A tremendous
number of inhibitors have been claimed to be in-
hibitors of PLA2 activity. PLA2 inhibitors are cur-
rently being investigated, using classical inflam-
matory models.[12] Table I shows selected
inhibitory agents with marked in vivo activity. For
adequate treatment it has been found necessary to
apply a cell-impermeable PLA2 inhibitor which af-
fects cell activity at the membrane but does not
enter the cell. Yedgar et al.[13] demonstrated im-
provement in bleomycin-induced lung injury in
hamsters after treatment with carmellose (carboxy-
methylcellulose) - linked phosphatidylethanola-
mine.
To date, only a few interventional studies with
PLA2 antagonists have been performed. Baboons
which were immunised with a neutralising mono-
clonal anti PLA2-II antibody showed significantly
attenuated hypotension after treatment with viable
Escherichia coli.[14] Moreover, lung vascular leak-
age in rats due to gut ischaemia and reperfusion
was blunted.[15]
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In discussing PLA2 inhibition, it must be kept
in mind that not only the formation of subsequent
proinflammatory lipid mediators is prevented but
also the generation of thromboregulatory, vas-
odilative and antiaggregatory PGI2 and PGE2 (fig.
1). To what extent PLA2 inhibitors will reach ther-
apeutic significance in inflammatory diseases will
need to be elucidated in further clinical studies.
PAF, a PLA2-dependent phospholipid, is an ex-
traordinarily potent mediator of shock[16] and in-
flammation. It exerts its biological effects by acti-
vating the PAF receptor, consequently stimulating
protein kinase C and increasing intracellular Ca++.
PAF is found in most biological fluids and is syn-
thesised in most cell types (fig. 2). Microvascular
permeability is markedly increased by PAF, allow-
ing fluids to leak out of the circulation. In the area
of haemodynamic effects, PAF is negatively ino-
tropic and lowers arterial blood pressure. It is a
potent platelet aggregator and leucocyte activator,
and it strongly promotes AA metabolism. It has
been proposed that it plays a crucial role in the
pathogenesis of rheumatoid arthritis, asthma,
endotoxin shock and acute renal transplant rejec-
tion.
In animal models, PAF caused bronchocon-
striction and increased airway resistance, pulmo-
nary hypertension and gastrointestinal ulceration.
Hence, selective PAF inhibition was investigated
with a variety of PAF receptor antagonists, which
were used in different animal models of sepsis and
gave promising results[17,18] (table II). Anti-inflam-
matory effects of PAF antagonists on experimental
models of arthritis have been published[19] indicat-
ing the modulation of different proinflammatory
cytokines. Data obtained in a model of immune
complex arthritis demonstrated controversial reg-
ulatory effects of the PAF antagonist bepafant
(WEB-2170) on eicosanoid release. Whereas
PGE2 and tumour necrosis factor (TNF) levels
dropped, LTB4 release was increased.[20] A clinical
trial carried out by Hilliquin and co-workers[21] re-
vealed improvement of rheumatoid arthritis after
administration of another PAF receptor antagonist,
ginkgolide B (BN-50730).
Dhainhaut et al.[22] performed a placebo-
controlled, double-blind study including 262 pa-
tients with sepsis syndrome. Besides their standard
supportive therapy, patients received the PAF re-
ceptor antagonist BN-52021 twice daily (120mg)
over 4 days, or placebo. The overall 28-day mor-
tality in the BN-52021 group did not differ signif-
icantly from the placebo group but in the subgroup
of patients with Gram-negative sepsis BN-52021
significantly reduced mortality (57% placebo vs
33% BN-52021). Subsequent studies (n = 608) did
not confirm any benefit from PAF receptor antag-
onism on the overall mortality.[23]
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Controversial results have been obtained from
asthmatic patients[24,25] and individuals with psori-
asis.[26] Decreased serum levels of interleukin (IL)-
8 and IL-6 were detected after treatment with the
PAF antagonist lexipafant in human acute pancre-
atitis.[27] After the encouraging animal studies with
PAF antagonists, the few existing clinical trials in
fact demonstrated improvement of rheumatic con-
ditions but did not show beneficial effects on sur-
vival rates in sepsis. Hence, it remains to be eluci-
dated whether or not PAF-receptor antagonists can
reach significance in the therapy of the critically ill
patient.
A variety of substances that inhibit the COX
pathway have been investigated, including non-
steroidal anti-inflammatory drugs (NSAIDs).
These are commonly used for the treatment of in-
flammation, pain and fever. More than 25 NSAIDs
are currently available. These compounds are be-
lieved to act via inhibition of the COX enzyme,
which catalyses the conversion of AA to the pros-
taglandins and thromboxane (fig. 1). Although
available NSAIDs are efficacious anti-inflamma-
tory agents, serious adverse effects limit their use.
Two forms of COX have been identified, a
constitutively expressed COX-1 and a cytokine-
inducible COX-2. It has been suggested that
NSAID toxicity is due to inhibition of COX-1,
whereas therapeutic properties derive from COX-2
inhibition at the site of inflammation.[28,29] There-
fore, selective COX-2 inhibitors such as SC-58125
may exert anti-inflammatory effects without gas-
trointestinal toxicity[30] (table III). Recent clinical
trials have evaluated the efficacy of COX-2 inhib-
itors in the therapy of arthritis, pointing towards
sufficient symptom relief with an improved gastro-
intestinal tolerability.[31] Moreover, evidence has
accumulated that COX-2 inhibition could suppress
the growth of colorectal cancer.[32]
Studies investigating the effect of COX inhibi-
tors in septic conditions demonstrated that ibu-
profen was able to attenuate most of the adverse
consequences of endotoxin administration and to
prolong survival in an animal model.[33] Bernhard
et al.[34] recently reported reduced levels of PGI2
and thromboxane in septic patients after adminis-
tration of ibuprofen. Fever, tachycardia, oxygen
consumption and lactic acidosis were blunted,
whereas the development of shock, acute respira-
tory distress syndrome (ARDS) and mortality rate
were unaltered.[34]
While ibuprofen not only inhibits inflammatory
COX products such as thromboxane but also the
vasodilator PGI2, another interesting approach is
the inhalational application of PGI2 in the therapy
of acute respiratory distress to improve the venti-
lation-perfusion ratio (V/Q) in the lung.[35] Aero-
solised PGI2 selectively induces pulmonary vaso-
dilation and redistribution of blood flow from
shunt areas to well ventilated regions, thereby in-
creasing oxygenation in severe ARDS.[35] It ap-
pears that PGI2 is a valuable tool in the therapy of
V/Q mismatch. The beneficial and adverse effects
of COX inhibition suggest the combination of sys-
temic COX-2 inhibition and additional supplemen-
tation with aerosolised PGI2 supplementation in
acute lung failure, to control inflammation.
A further approach to the selective reduction of
COX-induced vasoconstriction and platelet aggre-
gation without blockade of PGI2 is to antagonise
TXA2 synthesis. In a model of coronary thrombo-
sis, Guth and Müller[36] demonstrated antithrom-
botic properties of samixogrel (DTTX-30SE), a
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combined TXA2 receptor antagonist and synthase
inhibitor.[36] Thus, exclusive inhibition of TXA2
generation might be a helpful tool in preventing
vasoconstriction and platelet aggregation.
LTs are potent proinflammatory agents involved
in the pathophysiology of various inflammatory
diseases such as asthma, psoriasis, rheumatoid ar-
thritis and ulcerative colitis.[37] Therefore, many
anti-LT compounds have been developed which se-
lectively block either LT receptor sites or enzymes
related to their biosynthesis. Table IV gives a syn-
opsis of these drugs and their effects. Both catego-
ries of agents have been shown to decrease bron-
chial obstruction in asthma,[38,39] suggesting that
LTs and the 5-lipoxygenase products of AA are in-
volved in sustaining the acute airway response that
occurs after bronchial provocation in patients with
mild to moderate asthma.
LT antagonists and 5-lipoxygenase inhibitors
seem to be promising therapeutic tools but they are
unlikely to dominate the further therapy of asthma.
One of the main advantages for their use is that
they can be given orally.[40] Nickerson-Nutter and
Medvedeff[41] demonstrated the efficacy of the
combination of LT synthesis inhibitors and
cyclooxygenase inhibitors in models of rheuma-
toid arthritis. With regard to the chemotactic prop-
erties of LTB4, specific receptor antagonists have
been designed to control LTB4 effects. It has been
demonstrated that LY-293111 reduces upregula-
tion of the macrophage and neutrophil adhesion
molecule CD11b/CD18.[42] Moreover, this LTB4
receptor antagonist decreased the number of neu-
trophils in bronchoalveolar lavage fluid of patients
with allergen-sensitive asthma.[43] LTB4 antago-
nism could be a therapeutic approach in LTB4-
dependent disorders, such as ulcerative colitis or
psoriasis.
To date, no data are available concerning the use
of these agents in septic patients. Whether the in-
hibition of LTs might be useful as a strategy for
controlling proinflammatory lipid mediators will
need to be assessed in future clinical studies.
After the epidemiological studies of Dyerberg
et al.,[44] in which it was shown that Greenland
Eskimos have a lower incidence of thrombosis,
coronary heart disease and myocardial infarction,
interest was focused on -3-PUFAs, which are
contained in fish oils. Numerous studies have been
carried out, which showed beneficial properties of
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-3-PUFAs in various diseases (table V).[45] In our
own studies we demonstrated that parenteral -3-
PUFAs were rapidly incorporated into lung tissue
and reduced both vascular resistance and endo-
thelial permeability in the pulmonary circulation,
thus blunting oedema formation.[46]
The beneficial effects of -3-PUFAs seem to be
related to the uptake of EPA into cellular mem-
branes after dietary or parenteral application, and
its subsequent metabolism. In states of inflamma-
tion, EPA is released to compete with AA for me-
tabolism at the cyclooxygenase and 5-lipoxy-
genase levels (fig. 1). The metabolites of EPA
(pentaene-LTs, triene-PGs and TXA3) have less
proinflammatory and chemotactic potency than the
substances derived from AA (tetraene-LTs, diene-
PGs and TXA2). Considering the massive synthesis
of lipid mediators during inflammatory reactions,
supplementation of parenteral or enteral feeding
with -3 fatty acids seems to be a promising ther-
apeutic approach in inflammatory disorders, acting
by modulating the lipid mediator spectrum.
Lipid mediators are local mediators which act
in the intercellular microenvironments, where they
reach considerable levels. They are released from
various tissues and cells and usually develop their
effects at the site of production because of their
short half-life and rapid enzymatic inactivation.
Numerous mediators stimulate the lipid mediator
cascade generating pro-inflammatory eicosanoids
which increase their own synthesis via positive
feedback loops. As a consequence, cascade sys-
tems which are essential for host defence may be-
come self-perpetuating and independent of the
original stimuli, and finally cause tissue damage.
Research efforts of the past few decades have re-
sulted in the development of therapeutic interven-
tions at different sites of the inflammatory reaction.
To date, a broad spectrum of different enzyme in-
hibitors and receptor antagonists has been investi-
gated, showing a variety of effects on the course of
diseases. Animal studies and in vitro investigations
have revealed important beneficial anti-inflamma-
tory and immune modulating properties of lipid
mediator antagonism.
Inflammation and critical illness is a multifac-
torial process. Thus, it seems unlikely that pharma-
cological intervention to modulate the release of
lipid mediators will be the magic bullet to improve
patient outcome. The research efforts of recent
years, however, contribute to a better under-
standing of the pathophysiological impact of lipid
mediators in inflammatory disorders and offer new
therapeutic approaches.
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